enGene Therapeutics Inc. (ENGN): Valuation
TTM figures as of July 31, 2026
enGene Therapeutics Inc. trades at a -86.21% free-cash-flow yield. That FCF yield is higher than 9% of its own month-end history back to 2023.
Earnings yield -108.07%. Net cash $241.0M.
35 month-end valuation observations are on file, starting October 2023.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is ENGN cheap versus its own history?
enGene Therapeutics Inc. trades at a -86.21% free-cash-flow yield. That FCF yield is higher than 9% of its own month-end history back to 2023.
What is ENGN's free-cash-flow yield?
enGene Therapeutics Inc. currently yields -86.21% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.